Full-Life Technologies

Full-Life Technologies will participate in the 43rd Annual J.P. Morgan Healthcare Conference being held January 13-16, 2025 in San Francisco, California, USA. Julie Wu (President & Chief Financial Officer), Fa Liu (Chief Scientific Officer) and Oliver Froescheis (Senior Vice President of Corporate Development) will attend and host meetings. We look forward to speaking with you on the site!

Full-Life is building a cutting-edge manufacturing facility in Belgium to produce GMP-level Ac-225 radioisotope and radiolabeled drug product.    Under full capacity, it will provide Ac-225 therapies to tens of thousands of cancer patients each year once operational!   Come and check out with Philippe van Put the amazing progress we have made so far!

Full-Life Technologies will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 13:30 P.M. Greenwich Mean Time. Julie Wu (President & Chief Financial Officer), Philippe van Put (General Manger, Europe), and HH Ting (Co-founder & Chief Strategy Officer) will attend the Conference. We look forward to communicating with you on the site!

Full-Life Technologies will be presenting at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM"), which will be held in Hamburg, Germany, from October 19-23, 2024. Juan Zhang, Ph.D, Senior Vice President and Head of Biology, and Taishan Hu, Ph.D, Senior Vice President and Head of Medicinal Chemistry, will give three preclinical presentations which have been accepted as Top Rated Oral Presentation ("TROP").   Join us and continue to follow us! We look forward to communicating with you on the site!

Full-Life Technologies will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Lanny Sun, Co-founder, Chairman & Chief Executive Officer, will deliver a corporate presentation on Sept. 6, 2024, 1:50 to 2:25 p.m. ET. Join us and continue to follow us. We look forward to communicating with you on the site！

Full-Life Technologies, today announced the appointment of Ted Myles to Full-Life's Board of Directors. Mr. Myles will serve as chairman of the audit committee and as a member of the compensation committee of the Board. #FullLife #BoardofDirectors #Radiotherapeutics #TedMyles

Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets. #FullLife #SKBiopharmaceuticals #SKBP #FL091 #Licensing #Agreement

Congratulations to the outstanding achievements of Full-Life's Development Team based in Heidelberg, Germany! 🎉 Their relentless dedication and hard work have led to significant milestones for Full-Life, including: 💠 Receiving clearance of the IND application from the FDA for clinical trials of ²²⁵Ac-FL-020. 💠 Being granted the FDA Fast Track Designation for ²²⁵Ac-FL-020. These accomplishments demonstrate their commitment to advancing medical innovation and exploring new possibilities. Their efforts will pave the way for new and effective treatment options that can significantly benefit patients in need. #FullLifeTechnologies #DevelopmentTeam #Achievement #Innovation #Healthcare #FDA #IND #FastTrackDesignation #Ac225 #FL020 #radiotherapeutic

Full-Life Technologies today announced that the FDA has granted Fast Track Designation for ²²⁵Ac-FL-020, the company's lead radiopharmaceutical, which targets PSMA, for the treatment of mCRPC. #FullLifeTechnologies #FDA #225Ac #FL020 #mCRPC #PSMA #FastTrackDesignation

Shanghai, China, and Heidelberg, Germany – June 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting. #SNMMI2024 #Ac225 #Lu177 #NTSR1 #FL091 #FullLife #Radiopharmaceuticals